Investing.comDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 21:35:49·⟳ 抓取 21:36:40 +51s·⚡ 决策 10-08 21:37:42 +1m02s·19.0 天前
Nurix Therapeutics财报前瞻：市场关注Q3收入能否环比反弹，但正式业绩尚未发布
该文章只是盘中考前财报的预期汇总，实际Q3结果尚未发布；所列管线和合作进展均为数日早前已披露信息，未提供足以建立新多头或空头头寸的增量事实。
📄 原文Investing.com↗ 原文
Nurix Therapeutics earnings in spotlight amid pipeline gains
By Investing.com Advertisement Advertisement Nurix Therapeutics earnings in spotlight amid pipeline gains Earnings Publ…
不做 Nurix Therapeutics Inc.（NRIX.US）
财报前瞻没有新增业绩或临床事实，正式Q3结果尚未发布；当前方向和预期差不清，不在盘中提前开仓。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Nurix将在周五公布财报，市场已明确预期收入2360万美元、EPS亏损0.61美元；当前报道只是前瞻和旧催化汇总，方向与预期差均不清晰，等待正式财报更合适。
🔎 新鲜度:最早出现 2026-10-08 · 扩散 low · price-in 风险 medium ↗
关键理由
- 正式业绩、指引和临床更新尚未发布，当前没有可验证的正向或负向surprise。
- 文章中的首例患者入组、700万美元Pfizer里程碑及Gilead续约均非本次新增事实。
主要风险
- 若在正式财报前仅凭分析师乐观评级或目标价追入，容易在业绩公布时承受临床-stage生物医药股的高波动。
- 该公司收入主要由合作里程碑确认时点驱动，即便实际收入低于预期也可能造成短线大幅重定价。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-08 · 影响 weakens
文章本身指出上一季度收入仅904万美元，较预期低43%，且公司仍未盈利、收入依赖不规律的合作里程碑。
检索:Nurix Therapeutics recent earnings miss revenue shortfall bexobrutideg risks cash runway 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例缺口支持在正式财报前回避，而不是提前做多或做空NRIX。
方向:未使用历史先例：当前信号不是业绩本身，而是财报前预期汇总，做同类财报行情的先例统计无法回答本文是否具备新增edge。
涨幅量级:没有可用于设定止盈止损的高相似、同相位对齐样本。
形态:未从本文建立方向性交易，因此不以历史涨跌模式推断周五财报表现。
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 32 ms
{"result": "search_processed_events:agent query=`nurix bexobrutideg venetoclax phase 1b/2 first patient cll | nurix pfizer $7 million milestone gilead collaboration extension | nurix therapeutics nrix q3 fiscal 2026 earnings prev`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen
原文全文
展开原文 · 8,674 字
Nurix Therapeutics earnings in spotlight amid pipeline gains By Investing.com
Advertisement
Advertisement
Nurix Therapeutics earnings in spotlight amid pipeline gains
Earnings
Published
Oct 08, 2026, 09:35 AM
Nurix Therapeutics earnings in spotlight amid pipeline gains
View all comments (0)
0
Nurix Therapeutics earnings in spotlight amid pipeline gains
View all comments (0)
0
© Reuters
In this article:
GILD
-0.44%
PFE
-0.48%
RO
-0.87%
NRIX
-2.27%
Nurix Therapeutics Inc.
is set to report third-quarter fiscal 2026 results on Friday, with investors eager to see whether the clinical-stage biotech can deliver a sharp revenue rebound after badly missing expectations three months ago.
The Brisbane, Calif.-based company just days ago announced the first patient enrolled in a Phase 1b/2 study combining its lead drug candidate bexobrutideg with venetoclax for chronic lymphocytic leukemia, adding to recent momentum that includes a $7 million milestone from
Pfizer
and a research term extension with
Gilead Sciences
.
Analysts expect
Nurix
to post a loss of $0.61 per share on revenue of $23.6 million for the quarter ended August, representing significant sequential improvement from the prior quarter’s $0.81 loss on $9.04 million in revenue. The narrower expected loss would mark improvement from the year-ago period’s loss of $1.03 per share, though the company remains unprofitable as it advances its protein degradation pipeline.
EPS estimates have remained flat over the past 60 days, as have revenue estimates, suggesting analysts have maintained stable expectations heading into the report. Wall Street sentiment on the stock remains decidedly bullish: 13 of 14 analysts rate Nurix a buy, with a consensus price target of $33.93 implying nearly 50% upside from the current $22.73 share price. The stock has more than doubled from its 52-week low of $9.00, though it remains below its recent high of $28.23.
What Investors Are Watching
The primary question is whether Nurix can deliver on its $23.6 million revenue forecast after last quarter’s substantial miss, when actual revenue of $9.04 million fell 43% short of the $15.92 million analysts expected. For a clinical-stage company like Nurix, with a market capitalization of $2.36 billion, revenue is largely driven by the timing of partnership milestones and collaboration payments rather than product sales.
Investors will scrutinize updates on bexobrutideg, the company’s investigational BTK degrader being co-developed with
Roche
for B-cell malignancies. The drug is currently in a pivotal Phase 2 trial and a confirmatory Phase 3 study is planned to support global registration in relapsed/refractory chronic lymphocytic leukemia. Recent enrollment in the venetoclax combination study could open additional development pathways.
Any commentary on the company’s broader partnership portfolio will also be closely monitored, given the recent milestone achievements with
Pfizer
and the
Gilead
collaboration extension. These partnerships provide crucial funding for Nurix’s research operations while it advances wholly owned programs including NX-1607, an immuno-oncology candidate.
Friday’s results could offer insight into whether Nurix’s clinical progress and partnership strategy are translating into more predictable revenue streams, or whether the biotech faces continued lumpiness in its financial performance as it works toward potential commercialization of its protein degradation platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Nurix Therapeutics earnings in spotlight amid pipeline gains
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,024.50
-154.7
-0.30%
US 500
7,775.20
-26.5
-0.34%
Dow Jones
51,022.04
-157.83
-0.31%
S&P 500
7,775.96
-25.81
-0.33%
Nasdaq
27,416.74
-121.96
-0.44%
S&P 500 VIX
15.40
+0.32
+2.12%
Dollar Index
102.09
+0.077
+0.08%
Crude Oil WTI Futures
92.28
+4.00
+4.53%
Brent Oil Futures
104.64
+4.44
+4.43%
Natural Gas Futures
3.247
+0.044
+1.37%
Gold Futures
4,150.12
+9.42
+0.23%
Silver Futures
59.40
-0.894
-1.48%
Copper Futures
6.601
-0.0485
-0.73%
US Soybeans Futures
1,290.50
-6.50
-0.50%
U.S. 10Y
5.29
+0.012
+0.23%
U.S. 30Y
5.662
+0.001
+0.02%
U.S. 5Y
5.05
+0.029
+0.58%
U.S. 3M
4.151
0.000
0.00%
US 10Y T-Note Futures
104.31
-0.17
-0.16%
Euro Bund Futures
120.86
+0.05
+0.04%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
337.18
+0.51
+0.15%
NVDA
234.17
-3.30
-1.39%
GOOGL
354.29
+3.79
+1.08%
TSLA
374.06
-3.75
-0.99%
AMZN
259.13
-0.79
-0.30%
NFLX
70.04
+0.34
+0.48%
META
721.76
+0.45
+0.06%
Advertisement
Most Popular Articles
News
Analysis
Oil prices surge amid Mideast shipping attacks, U.S. Gulf coast disruptions
By Investing.co
...
Oct 08, 2026
Citi names 5 top chip picks ahead of Q3 earnings
By Investing.co
...
Oct 08, 2026
Up +32% MTD: As the tech rally spills over into these AI-picked restaurant plays
By Investing.co
...
Oct 08, 2026
AI debt deal wave reports; Applied Digital reports - what’s moving markets
By Investing.co
...
Oct 08, 2026
Wall Street posts first red session of October a day after notching a record close
By Investing.co
...
Oct 08, 2026
Micron Has Surged on the AI Boom - Is It Still a Buy?
By Antonio Rodr
...
Oct 06, 2026
9 Fundamentally Strong Stocks to Watch as Q3 Earnings Get Underway
By David Wagner
Oct 08, 2026
Nvidia Hits Another New High: Key Breakout and Retracement Targets to Watch
By Lee Yang
Oct 06, 2026
Worried Consumers Keep Spending: Here’s Why
By Michael Lebo
...
Oct 07, 2026
Q4 2026 Commodites Forecast: Will Gold and Silver Find a Bottom?
By Jeremy Wagne
...
Oct 07, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,077.58
-0.96%
2.40M
META
721.76
+0.06%
2.40M
NVDA
234.17
-1.39%
7.55M
PLTR
202.38
+4.26%
8.01M
GOOGL
354.29
+1.08%
3.35M
SNDK
1,657.75
-2.05%
647.86K
AMD
634.87
-1.70%
1.59M
Name
Last
Chg. %
Vol.
PLTR
202.38
+4.26%
8.01M
APA
45.44
+3.72%
244.68K
IT
191.27
+2.96%
15.78K
OXY
59.83
+2.78%
599.04K
NOW
141.37
+2.54%
1.32M
XOM
168.44
+2.68%
586.83K
CVX
210.80
+2.75%
397.86K
Name
Last
Chg. %
Vol.
SWKS
79.42
-4.81%
282.87K
ARM
282.01
-4.20%
558.27K
SMCI
43.33
-3.58%
3.11M
GLW
157.50
-3.52%
583.59K
CRWV
85.11
-3.78%
2.15M
APP
271.24
-3.57%
404.28K
MSTR
148.87
-2.94%
2.22M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,077.58
-0.96%
2.40M
SPCX
166.41
-0.71%
4.95M
NVDA
234.17
-1.39%
7.55M
SNDK
1,657.75
-2.05%
647.86K
APLD
23.690
-0.50%
9.29M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
Advertisement
Advertisement
Nurix Therapeutics earnings in spotlight amid pipeline gains
Earnings
Published
Oct 08, 2026, 09:35 AM
Nurix Therapeutics earnings in spotlight amid pipeline gains
View all comments (0)
0
Nurix Therapeutics earnings in spotlight amid pipeline gains
View all comments (0)
0
© Reuters
In this article:
GILD
-0.44%
PFE
-0.48%
RO
-0.87%
NRIX
-2.27%
Nurix Therapeutics Inc.
is set to report third-quarter fiscal 2026 results on Friday, with investors eager to see whether the clinical-stage biotech can deliver a sharp revenue rebound after badly missing expectations three months ago.
The Brisbane, Calif.-based company just days ago announced the first patient enrolled in a Phase 1b/2 study combining its lead drug candidate bexobrutideg with venetoclax for chronic lymphocytic leukemia, adding to recent momentum that includes a $7 million milestone from
Pfizer
and a research term extension with
Gilead Sciences
.
Analysts expect
Nurix
to post a loss of $0.61 per share on revenue of $23.6 million for the quarter ended August, representing significant sequential improvement from the prior quarter’s $0.81 loss on $9.04 million in revenue. The narrower expected loss would mark improvement from the year-ago period’s loss of $1.03 per share, though the company remains unprofitable as it advances its protein degradation pipeline.
EPS estimates have remained flat over the past 60 days, as have revenue estimates, suggesting analysts have maintained stable expectations heading into the report. Wall Street sentiment on the stock remains decidedly bullish: 13 of 14 analysts rate Nurix a buy, with a consensus price target of $33.93 implying nearly 50% upside from the current $22.73 share price. The stock has more than doubled from its 52-week low of $9.00, though it remains below its recent high of $28.23.
What Investors Are Watching
The primary question is whether Nurix can deliver on its $23.6 million revenue forecast after last quarter’s substantial miss, when actual revenue of $9.04 million fell 43% short of the $15.92 million analysts expected. For a clinical-stage company like Nurix, with a market capitalization of $2.36 billion, revenue is largely driven by the timing of partnership milestones and collaboration payments rather than product sales.
Investors will scrutinize updates on bexobrutideg, the company’s investigational BTK degrader being co-developed with
Roche
for B-cell malignancies. The drug is currently in a pivotal Phase 2 trial and a confirmatory Phase 3 study is planned to support global registration in relapsed/refractory chronic lymphocytic leukemia. Recent enrollment in the venetoclax combination study could open additional development pathways.
Any commentary on the company’s broader partnership portfolio will also be closely monitored, given the recent milestone achievements with
Pfizer
and the
Gilead
collaboration extension. These partnerships provide crucial funding for Nurix’s research operations while it advances wholly owned programs including NX-1607, an immuno-oncology candidate.
Friday’s results could offer insight into whether Nurix’s clinical progress and partnership strategy are translating into more predictable revenue streams, or whether the biotech faces continued lumpiness in its financial performance as it works toward potential commercialization of its protein degradation platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Nurix Therapeutics earnings in spotlight amid pipeline gains
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,024.50
-154.7
-0.30%
US 500
7,775.20
-26.5
-0.34%
Dow Jones
51,022.04
-157.83
-0.31%
S&P 500
7,775.96
-25.81
-0.33%
Nasdaq
27,416.74
-121.96
-0.44%
S&P 500 VIX
15.40
+0.32
+2.12%
Dollar Index
102.09
+0.077
+0.08%
Crude Oil WTI Futures
92.28
+4.00
+4.53%
Brent Oil Futures
104.64
+4.44
+4.43%
Natural Gas Futures
3.247
+0.044
+1.37%
Gold Futures
4,150.12
+9.42
+0.23%
Silver Futures
59.40
-0.894
-1.48%
Copper Futures
6.601
-0.0485
-0.73%
US Soybeans Futures
1,290.50
-6.50
-0.50%
U.S. 10Y
5.29
+0.012
+0.23%
U.S. 30Y
5.662
+0.001
+0.02%
U.S. 5Y
5.05
+0.029
+0.58%
U.S. 3M
4.151
0.000
0.00%
US 10Y T-Note Futures
104.31
-0.17
-0.16%
Euro Bund Futures
120.86
+0.05
+0.04%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
337.18
+0.51
+0.15%
NVDA
234.17
-3.30
-1.39%
GOOGL
354.29
+3.79
+1.08%
TSLA
374.06
-3.75
-0.99%
AMZN
259.13
-0.79
-0.30%
NFLX
70.04
+0.34
+0.48%
META
721.76
+0.45
+0.06%
Advertisement
Most Popular Articles
News
Analysis
Oil prices surge amid Mideast shipping attacks, U.S. Gulf coast disruptions
By Investing.co
...
Oct 08, 2026
Citi names 5 top chip picks ahead of Q3 earnings
By Investing.co
...
Oct 08, 2026
Up +32% MTD: As the tech rally spills over into these AI-picked restaurant plays
By Investing.co
...
Oct 08, 2026
AI debt deal wave reports; Applied Digital reports - what’s moving markets
By Investing.co
...
Oct 08, 2026
Wall Street posts first red session of October a day after notching a record close
By Investing.co
...
Oct 08, 2026
Micron Has Surged on the AI Boom - Is It Still a Buy?
By Antonio Rodr
...
Oct 06, 2026
9 Fundamentally Strong Stocks to Watch as Q3 Earnings Get Underway
By David Wagner
Oct 08, 2026
Nvidia Hits Another New High: Key Breakout and Retracement Targets to Watch
By Lee Yang
Oct 06, 2026
Worried Consumers Keep Spending: Here’s Why
By Michael Lebo
...
Oct 07, 2026
Q4 2026 Commodites Forecast: Will Gold and Silver Find a Bottom?
By Jeremy Wagne
...
Oct 07, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,077.58
-0.96%
2.40M
META
721.76
+0.06%
2.40M
NVDA
234.17
-1.39%
7.55M
PLTR
202.38
+4.26%
8.01M
GOOGL
354.29
+1.08%
3.35M
SNDK
1,657.75
-2.05%
647.86K
AMD
634.87
-1.70%
1.59M
Name
Last
Chg. %
Vol.
PLTR
202.38
+4.26%
8.01M
APA
45.44
+3.72%
244.68K
IT
191.27
+2.96%
15.78K
OXY
59.83
+2.78%
599.04K
NOW
141.37
+2.54%
1.32M
XOM
168.44
+2.68%
586.83K
CVX
210.80
+2.75%
397.86K
Name
Last
Chg. %
Vol.
SWKS
79.42
-4.81%
282.87K
ARM
282.01
-4.20%
558.27K
SMCI
43.33
-3.58%
3.11M
GLW
157.50
-3.52%
583.59K
CRWV
85.11
-3.78%
2.15M
APP
271.24
-3.57%
404.28K
MSTR
148.87
-2.94%
2.22M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,077.58
-0.96%
2.40M
SPCX
166.41
-0.71%
4.95M
NVDA
234.17
-1.39%
7.55M
SNDK
1,657.75
-2.05%
647.86K
APLD
23.690
-0.50%
9.29M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
5628184749· 2026-10-08 21:37 · doubao / doubao-seed-evolving-latest-version · 策略包0c89ec5cee9e当前